251 related articles for article (PubMed ID: 15481989)
21. N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor.
Beukers MW; Wanner MJ; Von Frijtag Drabbe Künzel JK; Klaasse EC; IJzerman AP; Koomen GJ
J Med Chem; 2003 Apr; 46(8):1492-503. PubMed ID: 12672250
[TBL] [Abstract][Full Text] [Related]
22. 5'-O-alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors.
van Tilburg EW; van der Klein PA; von Frijtag Drabbe Künzel J; de Groote M; Stannek C; Lorenzen A; IJzerman AP
J Med Chem; 2001 Aug; 44(18):2966-75. PubMed ID: 11520205
[TBL] [Abstract][Full Text] [Related]
23. 5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.
Da Settimo F; Primofiore G; Taliani S; Marini AM; La Motta C; Simorini F; Salerno S; Sergianni V; Tuccinardi T; Martinelli A; Cosimelli B; Greco G; Novellino E; Ciampi O; Trincavelli ML; Martini C
J Med Chem; 2007 Nov; 50(23):5676-84. PubMed ID: 17927167
[TBL] [Abstract][Full Text] [Related]
24. 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists.
Chang LC; Spanjersberg RF; von Frijtag Drabbe Künzel JK; Mulder-Krieger T; Brussee J; Ijzerman AP
J Med Chem; 2006 May; 49(10):2861-7. PubMed ID: 16686529
[TBL] [Abstract][Full Text] [Related]
25. New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists.
Baraldi PG; Preti D; Zaid AN; Saponaro G; Tabrizi MA; Baraldi S; Romagnoli R; Moorman AR; Varani K; Cosconati S; Di Maro S; Marinelli L; Novellino E; Borea PA
J Med Chem; 2011 Jul; 54(14):5205-20. PubMed ID: 21675777
[TBL] [Abstract][Full Text] [Related]
26. N6-substituted C5'-modified adenosines as A1 adenosine receptor agonists.
Ashton TD; Baker SP; Hutchinson SA; Scammells PJ
Bioorg Med Chem; 2008 Feb; 16(4):1861-73. PubMed ID: 18042389
[TBL] [Abstract][Full Text] [Related]
27. 3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor.
DeNinno MP; Masamune H; Chenard LK; DiRico KJ; Eller C; Etienne JB; Tickner JE; Kennedy SP; Knight DR; Kong J; Oleynek JJ; Tracey WR; Hill RJ
J Med Chem; 2003 Jan; 46(3):353-5. PubMed ID: 12540233
[TBL] [Abstract][Full Text] [Related]
28. New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists.
Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Varani K; Borea PA
J Med Chem; 2005 Jul; 48(15):5001-8. PubMed ID: 16033279
[TBL] [Abstract][Full Text] [Related]
29. Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-uronamides as highly potent and selective agonists at the human A3 adenosine receptor.
Jeong LS; Lee HW; Jacobson KA; Kim HO; Shin DH; Lee JA; Gao ZG; Lu C; Duong HT; Gunaga P; Lee SK; Jin DZ; Chun MW; Moon HR
J Med Chem; 2006 Jan; 49(1):273-81. PubMed ID: 16392812
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, biological assays and QSAR studies of N-(9-benzyl-2-phenyl-8-azapurin-6-yl)-amides as ligands for A1 adenosine receptors.
Giorgi I; Leonardi M; Pietra D; Biagi G; Borghini A; Massarelli I; Ciampi O; Bianucci AM
Bioorg Med Chem; 2009 Mar; 17(5):1817-30. PubMed ID: 19230680
[TBL] [Abstract][Full Text] [Related]
31. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Capelli F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Pedata F; Schiesaro A; Morizzo E; Moro S
J Med Chem; 2007 Aug; 50(17):4061-74. PubMed ID: 17665891
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
[TBL] [Abstract][Full Text] [Related]
33. The role of intraspinal adenosine A1 receptors in sympathetic regulation.
Peng SC; Ho CM; Ho ST; Tsai SK; Su CK
Eur J Pharmacol; 2004 May; 492(1):49-55. PubMed ID: 15145705
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of new N6-substituted adenosine-5'-N-methylcarboxamides as A3 adenosine receptor agonists.
Devine SM; Gregg A; Figler H; McIntosh K; Urmaliya V; Linden J; Pouton CW; White PJ; Bottle SE; Scammells PJ
Bioorg Med Chem; 2010 May; 18(9):3078-87. PubMed ID: 20385496
[TBL] [Abstract][Full Text] [Related]
35. QSAR study of N6-(substituted-phenylcarbamoyl) adenosine-5'-uronamides as agonist for A1 adenosine receptors.
Pérez González M; Terán Moldes Mdel C
Bull Math Biol; 2004 Jul; 66(4):907-20. PubMed ID: 15210326
[TBL] [Abstract][Full Text] [Related]
36. 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists.
Chang LC; Spanjersberg RF; von Frijtag Drabbe Künzel JK; Mulder-Krieger T; van den Hout G; Beukers MW; Brussee J; Ijzerman AP
J Med Chem; 2004 Dec; 47(26):6529-40. PubMed ID: 15588088
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
Cappellacci L; Franchetti P; Pasqualini M; Petrelli R; Vita P; Lavecchia A; Novellino E; Costa B; Martini C; Klotz KN; Grifantini M
J Med Chem; 2005 Mar; 48(5):1550-62. PubMed ID: 15743197
[TBL] [Abstract][Full Text] [Related]
38. A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor.
Chang LC; von Frijtag Drabbe Künzel JK; Mulder-Krieger T; Spanjersberg RF; Roerink SF; van den Hout G; Beukers MW; Brussee J; Ijzerman AP
J Med Chem; 2005 Mar; 48(6):2045-53. PubMed ID: 15771447
[TBL] [Abstract][Full Text] [Related]
39. QSAR of adenosine receptor antagonists. Part 3: Exploring physicochemical requirements for selective binding of 1,2,4-triazolo[5,1-i]purine derivatives with human adenosine A3 receptor subtype.
Roy K; Leonard JT; Sengupta C
Bioorg Med Chem Lett; 2004 Jul; 14(14):3705-9. PubMed ID: 15203147
[TBL] [Abstract][Full Text] [Related]
40. 4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Lenzi O; Colotta V; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Varani K; Marighetti F; Morizzo E; Moro S
J Med Chem; 2006 Jun; 49(13):3916-25. PubMed ID: 16789747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
